Operator: Greetings. And welcome to Aurinia Pharmaceuticals Incorporated Second Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode.
Operator: Greetings, and welcome to Aurinia Pharmaceuticals Inc. First Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode.
Aurinia Reports First Quarter 2021 Financial Results and Recent Operational Highlights
Over 250 patient start forms received by the end of the first quarter – – Cash and cash equivalents, and investments of $360.9 million at March 31, 2021 – – Conference call to be hosted today at 5:00 p.m. ET – Aurinia Pharmaceuticals Inc. today issued its financial results for the first quarter ended March 31, 2021. Amounts, unless specified otherwise, are expressed in U.S. dollars. “2021 started with the FDA … – Over 250 patient start forms received by the end of the first quarter – – Cash and cash equivalents, and investments of $360.9 million at March 31, 2021 – – Conference call to be hosted today at 5:00 p.m. ET –
Operator
Greetings, and welcome to the Aurinia Year-end 2020 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is recorded. It s now my pleasure to turn the call over to Glenn Schulman, Senior Vice President, Investor Relations. Please go ahead, sir.
Glenn Schulman
Senior Vice President, Corporate Communications and Investor Relations
Thank you, Kevin, and good afternoon, everyone. I m pleased to welcome you to today s call discussing Aurinia s fourth quarter and year-end financial results. Joining me on the call this afternoon are Peter Greenleaf, President and CEO of Aurinia; Neil Solomons, our Chief Medical Officer; Max Colao, Chief Commercial Officer; and Joe Miller, our Chief Financial Officer. This afternoon, just after 4:00 p.m., we issued a press release announcing our financial results and recent operational highlights, which is accessible from our website at www.auriniapharma.com and has been filed on a Form 8-K with the SEC as